Safety is the right question to ask first about any treatment delivered outside a hospital setting. The answer, for carefully selected patients receiving subcutaneous pembrolizumab with appropriate clinical oversight, is supported by evidence - but it depends on what that oversight looks like in practice.
What the clinical evidence shows
The safety profile of subcutaneous pembrolizumab was established in the KEYNOTE-D18 bioequivalence trial and subsequent real-world data. The subcutaneous formulation produces the same safety events as the IV formulation - immune-related adverse events of the same types and frequencies. What has not been demonstrated is any additional safety risk from the route of administration itself, when the drug is handled, stored, and administered correctly.
Subcutaneous injections have a well-established safety record across many drug classes. The pembrolizumab subcutaneous formulation has been specifically developed for administration in non-hospital settings and is approved for use by trained healthcare professionals outside of oncology day units.
The role of appropriate patient selection
Not every pembrolizumab patient is suitable for home treatment. Patients who are at higher risk of severe early reactions, who have complex medical needs requiring immediate hospital support, or whose living situation makes safe administration difficult are better managed in a clinical facility. Patient selection is the most important safety mechanism in any home treatment programme.
Our eligibility assessment includes explicit consideration of home treatment suitability - not just treatment eligibility. These are distinct questions, and both matter.
Our oversight model
Safe home-based pembrolizumab requires several components working together. A qualified oncology nurse administers every injection, with pre- and post-injection observations at each visit. A supervising oncologist reviews blood results before each cycle and is available for clinical queries between visits. Escalation pathways are documented and communicated to patients before treatment starts - so that if a problem arises, you know exactly who to call and what happens next.
Remote check-ins between cycles allow the clinical team to identify emerging side effects before they escalate. Most immune-related adverse events develop gradually and are detectable before they become serious - regular monitoring is the key to catching them early.
What "safe" means in this context
No cancer treatment is without risk. The risks of pembrolizumab - immune-related adverse events, in particular - exist whether the drug is given at home or in hospital. What safety in the home setting requires is that those risks are managed with the same rigour as they would be in a clinical facility: appropriate patient selection, qualified administration, robust monitoring, and clear escalation pathways. These are achievable - and they are what our programme is built around.
Have questions about safety and oversight?
Safety protocols are one of the things we cover in detail on the Welcome Call. Start with the eligibility check - it takes three minutes.
Check your eligibility